default author photo

Marlena Kaczmarek

European Centre for Disease Prevention and Control

Solna

Sweden

SCHOLARLY PAPERS

5

DOWNLOADS

565

TOTAL CITATIONS

3

Scholarly Papers (5)

1.

Effectiveness of Covid-19 Vaccines Administered in the 2023 Autumnal Campaigns in Europe: Results from the Vebis Primary Care Test-Negative Design Study, September 2023–January 2024

Number of pages: 27 Posted: 01 May 2024
Epiconcept, National Institute of Health Doutor Ricardo Jorge, Epiconcept, Carlos III Institute of Health - Communicable Diseases Department, Robert Koch Institute, Health Service Executive, Semmelweis University, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Croatian Institute of Public Health, Public Health Agency of Sweden, Romanian Institute of Science and Technology - National Institute of Research and Development for Microbiology and Immunology „Cantacuzino”, Carlos III Health Institute, Robert Koch Institute, University College Dublin (UCD), Semmelweis University, University of Paris-Saclay - Laboratoire de Microbiologie, National Health Institute Doutor Ricardo Jorge (INSA) - National Influenza Reference Laboratory, Instituto de Salud Pública y Laboral de Navarra, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Public Health Agency of Sweden, National Institute for Public Health and the Environment (RIVM), National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, Consejería de Sanidad, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 137 (534,155)
Citation 2

Abstract:

Loading...

COVID-19, vaccine effectiveness, multicentre study, test-negative design, Europe, SARS-CoV-2

2.

The Potential Bias Introduced into COVID-19 Vaccine Effectiveness Studies at Primary Care Level Due to the Availability of SARS-CoV-2 Tests in the General Population

Number of pages: 28 Posted: 12 Nov 2024
Epiconcept, Epiconcept, Carlos III Institute of Health - Communicable Diseases Department, National Institute for Public Health and the Environment (RIVM), Semmelweis University, National Institute of Health Doutor Ricardo Jorge, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Consejería de Sanidad - Dirección General de Salud Pública, Robert Koch Institute - Department for Infectious Disease Epidemiology, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Health Service Executive, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, NIVEL (Netherlands Institute for Health Services Research), Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - National Influenza Reference Laboratory, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Consejería de Sanidad - Dirección General de Salud Pública, Robert Koch Institute, Université Paris Saclay, Health Service Executive, Instituto de Salud Pública y Laboral de Navarra, National Institute for Public Health and the Environment (RIVM), National Institute for Public Health and the Environment (RIVM), European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 112 (630,858)
Citation 1

Abstract:

Loading...

COVID-19, Vaccine effectiveness, Test-negative design, Self-test, Bias, Directed acyclic graph, Simulation

3.

COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Number of pages: 20 Posted: 21 Mar 2025
Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health - Communicable Diseases Department, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Epiconcept, Subdirección General de Epidemiología y Vigilancia de la Salud, Health Service Executive, University of Paris-Saclay - Institut Pasteur, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Murcia Regional Health Council-IMIB, University College Dublin (UCD), University of Corsica, Robert Koch Institute - Department for Infectious Disease Epidemiology, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Semmelweis University, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 108 (649,907)

Abstract:

Loading...

COVID-19, vaccine effectiveness, SARS-CoV-2, Europe

4.

Effectiveness of XBB.1.5 Vaccines against Symptomatic SARS-CoV-2 Infection in Older Adults during the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

Number of pages: 17 Posted: 11 Jul 2024
Epiconcept - Epidemiology Department, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, NIVEL (Netherlands Institute for Health Services Research), National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Epiconcept, Consejería de Sanidad - Dirección General de Salud Pública, University College Dublin (UCD), University of Paris-Saclay - Laboratoire de Microbiologie, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute of Health Doutor Ricardo Jorge, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, National Institute for Public Health and the Environment (RIVM), National Institute of Health Doutor Ricardo Jorge, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 105 (664,543)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Primary care, Case-control study, Test-negative design, Multi-country study

5.

COVID-19 Vaccine Effectiveness Among Older Adults in 2025/26

Number of pages: 16 Posted: 12 Mar 2026 Last Revised: 20 Mar 2026
Epiconcept, Bruno Kessler Foundation, Carlos III Health Institute, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Robert Koch Institute - Department for Infectious Disease Epidemiology, Croatian Institute of Public Health, Semmelweis University, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Cantacuzino National Military Medical Institute for Research and Development, Public Health Agency of Sweden, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Istituto Superiore di Sanità, The Directorate General of Public Health, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Paris-Saclay - Institut Pasteur, Robert Koch Institute - Department for Infectious Disease Epidemiology, Istituto Superiore di Sanità - Department of Infectious Diseases, Consejería de Sanidad - Dirección General de Salud Pública, Instituto de Salud Pública y Laboral de Navarra, The Health Service Executive-Health Protection Surveillance Centre (HSE-HPSC), University of Corsica, Robert Koch Institute, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 103 (674,591)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Europe